Clinical Trials · NCT04504370
Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- PegBio Co., Ltd.
- Enrollment
- 273
- Start date
- Apr 2020
- Locations
- 1 site, China
- Primary endpoint
- Change in HbA1c